

Eli Muchtar

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8239160/eli-muchtar-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

262
papers

2,918
citations

27
h-index

46
g-index

297
ext. papers

3,835
ext. citations

4
avg, IF

5.24
L-index

#	Paper	IF	Citations
262	Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4851-63	5.9	450
261	Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. <i>Blood</i> , 2017 , 129, 2111-2119	2.2	181
260	Restrictive Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. <i>Circulation Research</i> , 2017 , 121, 819-837	15.7	139
259	How I treat cryoglobulinemia. <i>Blood</i> , 2017 , 129, 289-298	2.2	76
258	Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. <i>Leukemia</i> , 2017 , 31, 1562-1569	10.7	70
257	Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 531-536	10.7	60
256	Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. <i>Bone Marrow Transplantation</i> , 2019 , 54, 353-367	4.4	51
255	Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. <i>Leukemia</i> , 2018 , 32, 2240-2249	10.7	49
254	Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2009 , 45, 3131-48	7.5	49
253	Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy. <i>Acta Haematologica</i> , 2016 , 135, 172-90	2.7	47
252	The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment. <i>Blood</i> , 2017 , 129, 82-87	2.2	41
251	Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2018 , 25, 86-92	2.7	40
250	A practical review on carfilzomib in multiple myeloma. <i>European Journal of Haematology</i> , 2016 , 96, 564-738		38
249	Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment. <i>Therapeutic Advances in Hematology</i> , 2016 , 7, 187-95	5.7	38
248	Autologous stem cell transplant for multiple myeloma patients 70 years or older. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1449-1455	4.4	37
247	Surgical site infections following craniotomy focusing on possible post-operative acquisition of infection: prospective cohort study. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2013 , 32, 1511-6	5.3	35
246	Systemic amyloidosis from A (AA) to T (ATTR): a review. <i>Journal of Internal Medicine</i> , 2021 , 289, 268-292	10.8	35

245	A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry-Verified Typing. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 472-483	6.4	33
244	Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 598-605	4.7	32
243	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020 , 105, 765-773	6.6	31
242	Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1354-1361	6.4	30
241	Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio. <i>Leukemia</i> , 2019 , 33, 527-531	10.7	30
240	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Leukemia</i> , 2017 , 31, 92-99	10.7	29
239	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2712-2719	1.9	28
238	Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era. <i>Blood Cancer Journal</i> , 2016 , 6, e512	7	28
237	Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. <i>Annals of Medicine</i> , 2017 , 49, 545-551	1.5	27
236	Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis. <i>American Journal of Hematology</i> , 2020 , 95, 497-502	7.1	27
235	Ten-year survivors in AL amyloidosis: characteristics and treatment pattern. <i>British Journal of Haematology</i> , 2019 , 187, 588-594	4.5	26
234	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018 , 183, 421-427	4.5	25
233	Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1020-1026	7.1	25
232	Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. <i>British Journal of Haematology</i> , 2016 , 172, 89-96	4.5	25
231	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020 , 188, 394-403	4.5	23
230	Venetoclax for the treatment of translocation (11;14) AL amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 55	7	22
229	Continued improvement in survival in multiple myeloma (MM) including high-risk patients.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 8039-8039	2.2	22
228	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020 , 34, 1373-1382	10.7	22

227	New developments in diagnosis, risk assessment and management in systemic amyloidosis. <i>Blood Reviews</i> , 2020 , 40, 100636	11.1	21
226	Survival impact of achieving minimal residual negativity by multi-parametric flow cytometry in AL amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020 , 27, 13-16	2.7	21
225	Revisiting conditioning dose in newly diagnosed light chain amyloidosis undergoing frontline autologous stem cell transplant: impact on response and survival. <i>Bone Marrow Transplantation</i> , 2017 , 52, 1126-1132	4.4	20
224	Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation. <i>Leukemia</i> , 2018 , 32, 712-718	10.7	20
223	The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. <i>Bone Marrow Transplantation</i> , 2017 , 52, 34-40	4.4	20
222	Posttransplantation lymphoproliferative disorder in lung transplant recipients: a 15-year single institution experience. <i>Transplantation</i> , 2013 , 96, 657-63	1.8	20
221	Staging systems use for risk stratification of systemic amyloidosis in the era of high-sensitivity troponin T assay. <i>Blood</i> , 2019 , 133, 763-766	2.2	20
220	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020 , 9, 3390-3399	4.8	19
219	Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation. <i>Haematologica</i> , 2017 , 102, 1439-1445	6.6	19
218	Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis. <i>Leukemia</i> , 2020 , 34, 1135-1143	10.7	19
217	Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis. <i>Blood Cancer Journal</i> , 2020 , 10, 20	7	18
216	Benchmarking inappropriate empirical antibiotic treatment. <i>Clinical Microbiology and Infection</i> , 2013 , 19, 629-33	9.5	18
215	Impact of MYD88 mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020 , 95, 274-281	7.1	18
214	Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma. <i>Blood Advances</i> , 2018 , 2, 3149-3154	7.8	17
213	First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis. <i>Blood</i> , 2016 , 127, 2936-8	2.2	16
212	Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells. <i>American Journal of Hematology</i> , 2020 , 95, 310-315	7.1	16
211	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019 , 33, 790-794	10.7	16
210	Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. <i>Blood Advances</i> , 2018 , 2, 769-776	7.8	16

209	Comparative analysis of staging systems in AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 811-814	10.7	15
208	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018 , 93, 1384-1393	7.1	15
207	Utility and prognostic value of F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2018 , 93, 1518-1523 ¹	7.1	15
206	Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. <i>British Journal of Haematology</i> , 2017 , 178, 888-895	4.5	14
205	The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. <i>The Cochrane Library</i> , 2013 , CD009594	5.2	13
204	Prognostic Significance of Holter Monitor Findings in Patients With Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 455-464	6.4	13
203	Monoclonal gammopathy plus positive amyloid biopsy does not always equal AL amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, E141-E143	7.1	13
202	Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma. <i>Blood Cancer Journal</i> , 2018 , 8, 106	7	13
201	Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2360-2364	4.7	13
200	Impact of pre-transplant bone marrow plasma cell percentage on post-transplant response and survival in newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 308-315	1.9	12
199	Long-term outcomes of IMiD-based trials in patients with immunoglobulin light-chain amyloidosis: a pooled analysis. <i>Blood Cancer Journal</i> , 2020 , 10, 4	7	12
198	Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2127-2132	4.7	12
197	Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 864-864	2.2	12
196	Outcomes of light-chain amyloidosis patients treated with first-line bortezomib: a collaborative retrospective multicenter assessment. <i>European Journal of Haematology</i> , 2016 , 96, 136-43	3.8	12
195	Glycosylation of immunoglobulin light chains is highly prevalent in cold agglutinin disease. <i>American Journal of Hematology</i> , 2020 , 95, E222-E225	7.1	11
194	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020 , 105, 2675-2678	6.6	11
193	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2383-2388	1.9	11
192	Newer Therapies for Amyloid Cardiomyopathy. <i>Current Heart Failure Reports</i> , 2016 , 13, 237-246	2.8	11

191	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. <i>American Journal of Hematology</i> , 2019 , 94, 338-345	7.1	11
190	Prevalence and predictors of thyroid functional abnormalities in newly diagnosed AL amyloidosis. <i>Journal of Internal Medicine</i> , 2017 , 281, 611-619	10.8	10
189	Myeloma in scar tissue--an underreported phenomenon or an emerging entity in the novel agents era? A single center series. <i>Acta Haematologica</i> , 2014 , 132, 39-44	2.7	10
188	Revisiting complete response in light chain amyloidosis. <i>Leukemia</i> , 2020 , 34, 1472-1475	10.7	10
187	Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio. <i>American Journal of Hematology</i> , 2020 , 95, 1280-1287	7.1	10
186	Acute promyelocytic leukemia with isochromosome 17q and cryptic PML-RARA successfully treated with all-trans retinoic acid and arsenic trioxide. <i>Cancer Genetics</i> , 2015 , 208, 575-9	2.3	9
185	Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2018 , 182, 71-77	4.5	9
184	Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. <i>Leukemia and Lymphoma</i> , 2018 , 59, 288-299	1.9	9
183	Impact of consolidation therapy post autologous stem cell transplant in patients with light chain amyloidosis. <i>American Journal of Hematology</i> , 2019 , 94, 1066-1071	7.1	9
182	First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience. <i>Leukemia Research</i> , 2014 , 38, 1401-6	2.7	9
181	Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type. <i>Haematologica</i> , 2016 , 101, 1102-9	6.6	9
180	Implications of detecting serum monoclonal protein by MASS-fix following stem cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2021 , 193, 380-385	4.5	9
179	Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018 , 132, 304-304	2.2	8
178	MASS-FIX for the detection of monoclonal proteins and light chain N-glycosylation in routine clinical practice: a cross-sectional study of 6315 patients. <i>Blood Cancer Journal</i> , 2021 , 11, 50	7	8
177	Treatment of AL Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement 2020 Update. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 1546-1577	6.4	8
176	Bone mineral density utilization in patients with newly diagnosed multiple myeloma. <i>Hematological Oncology</i> , 2017 , 35, 703-710	1.3	7
175	First report of MYD88 somatic mutation in IgM-associated light chain amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 42-43	2.7	7
174	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021 , 100, 143-155	3	7

173	The impact of re-induction prior to salvage autologous stem cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2019 , 54, 2039-2050	4.4	6
172	Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 1520-1525	4.7	6
171	Updates in the Diagnosis and Management of AL Amyloidosis. <i>Current Hematologic Malignancy Reports</i> , 2020 , 15, 155-167	4.4	6
170	Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 637-642	7.1	6
169	Uninvolved immunoglobulins predicting hematological response in newly diagnosed AL amyloidosis. <i>Leukemia Research</i> , 2016 , 41, 56-61	2.7	6
168	Acquired transthyretin amyloidosis after domino liver transplant: Phenotypic correlation, implication of liver retransplantation. <i>Journal of the Neurological Sciences</i> , 2017 , 379, 192-197	3.2	6
167	Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7525-7525	2.2	6
166	Hematopoietic score predicts outcomes in newly diagnosed multiple myeloma patients. <i>American Journal of Hematology</i> , 2020 , 95, 4-9	7.1	6
165	Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials. <i>American Journal of Hematology</i> , 2021 , 96, 1131-1136	7.1	6
164	Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2132-2137	4.4	5
163	Daratumumab as successful initial therapy for AL amyloidosis with nerve involvement. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1752-1755	1.9	5
162	Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response. <i>Bone Marrow Transplantation</i> , 2019 , 54, 442-447	4.4	5
161	High-risk multiple myeloma: a multifaceted entity, multiple therapeutic challenges. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1283-1296	1.9	5
160	Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. <i>Leukemia</i> , 2021 ,	10.7	5
159	Delayed neutrophil engraftment in patients receiving Daratumumab as part of their first induction regimen for multiple myeloma. <i>American Journal of Hematology</i> , 2020 , 95, E8-E10	7.1	5
158	Cytogenetic Features and Clinical Outcomes of Patients With Non-secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 53-56	2	5
157	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020 , 95, E57-E60	7.1	5
156	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020 , 25, 974-980	5.7	5

155	A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis. <i>Kidney International</i> , 2021 , 99, 707-715	9.9	5
154	Autologous stem cell transplantation for multiple myeloma patients aged ≥ 75 treated with novel agents. <i>Bone Marrow Transplantation</i> , 2021 , 56, 1144-1150	4.4	5
153	Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis. <i>Leukemia</i> , 2019 , 33, 1268-1272	10.7	4
152	The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?. <i>Blood Cancer Journal</i> , 2020 , 10, 52	7	4
151	Depth of organ response in AL amyloidosis is associated with improved survival: new proposed organ response criteria. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019 , 26, 101-102	2.7	4
150	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2021 , 97, 90	7.1	4
149	Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 677-687	6.4	4
148	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021 , 138, 149-159	2.2	4
147	Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design. <i>Leukemia</i> , 2021 , 35, 3604-3607	10.7	4
146	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021 , 11, 86	7	4
145	Utility of serum free light chain ratio in response definition in patients with multiple myeloma. <i>Blood Advances</i> , 2020 , 4, 322-326	7.8	4
144	Disease monitoring with quantitative serum IgA levels provides a more reliable response assessment in multiple myeloma patients. <i>Leukemia</i> , 2021 , 35, 1428-1437	10.7	4
143	Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 40-41	2.7	3
142	The Clinical Implication of Incidental Prostatic Amyloidosis. <i>Urology</i> , 2020 , 145, 253-257	1.6	3
141	Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020 , 20, 596-601	2	3
140	The role of stem cell transplantation in Waldenström's macroglobulinemia. <i>Best Practice and Research in Clinical Haematology</i> , 2016 , 29, 229-240	4.2	3
139	Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 2157-2159	4.7	3
138	Comparison of different techniques to identify cardiac involvement in immunoglobulin light chain (AL) amyloidosis. <i>Blood Advances</i> , 2019 , 3, 1226-1229	7.8	3

137	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019 , 134, 4306-4306	2.2	3
136	Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020 , 136, 36-37	2.2	3
135	The Challenges in Chemotherapy and Stem Cell Transplantation for Light-Chain Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020 , 36, 384-395	3.8	3
134	Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1077-1081	4.4	3
133	Characterization and prognostic implication of delayed complete response in AL amyloidosis. <i>European Journal of Haematology</i> , 2021 , 106, 354-361	3.8	3
132	Prognostic restaging after treatment initiation in patients with AL amyloidosis. <i>Blood Advances</i> , 2021 , 5, 1029-1036	7.8	3
131	Coagulation Abnormalities in Light Chain Amyloidosis. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 377-387	6.4	3
130	Elevated pre-transplant C-reactive protein identifies a high-risk subgroup in multiple myeloma patients undergoing delayed autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018 , 53, 155-161	4.4	3
129	Comparison of the current renal staging, progression and response criteria to predict renal survival in AL amyloidosis using a Mayo cohort. <i>American Journal of Hematology</i> , 2021 , 96, 446-454	7.1	3
128	Persistent carbapenem-resistant <i>Klebsiella pneumoniae</i> bacteremia in a patient with acute lymphoblastic leukemia. <i>Israel Medical Association Journal</i> , 2012 , 14, 195-7	0.9	3
127	Early intervention in asymptomatic chronic lymphocytic leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2021 , 19, 92-103	0.6	3
126	"Real-life" data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma-the Mayo Clinic experience. <i>Blood Cancer Journal</i> , 2021 , 11, 196	7	3
125	Prognostic Role of Beta-2 Microglobulin in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1402-1405	4.7	2
124	Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.. <i>Leukemia</i> , 2022 ,	10.7	2
123	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. <i>Blood</i> , 2019 , 134, 3050-3050	2.2	2
122	Prognostic Implications of Serum Monoclonal Protein Positivity By Mass-Fix in Bone Marrow Minimal Residual Disease Negative (MRD-) Patients with Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4386-4386	2.2	2
121	Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone for Treatment of Previously Untreated Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 52-53	2.2	2
120	Clinical and cytogenetic features of nonsecretory multiple myeloma (NSMM) in the era of novel agent induction therapy: The Mayo Clinic experience.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e19519-e19519	2.2	2

119	"Real-Life" Data of the Efficacy and Safety of Belantamab Mafodotin in Relapsed Multiple Myeloma- the Mayo Clinic Experience. <i>Blood</i> , 2021 , 138, 1639-1639	2.2	2
118	Plasma Cell Proliferative Index Is an Independent Predictor of Progression in Smoldering Multiple Myeloma. <i>Blood</i> , 2018 , 132, 3160-3160	2.2	2
117	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021 , 96, 945-953	7.1	2
116	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma: A Cross-analysis of a Population-based Registry and a Tertiary Care Center. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 451-460.e2	2	2
115	Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) Amyloidosis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 589.e1-589.e6		2
114	Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2021 , 56, 928-935	4.4	2
113	Novel imaging techniques using F-florbetapir PET/MRI can guide fascicular nerve biopsy in amyloid multiple mononeuropathy. <i>Muscle and Nerve</i> , 2021 , 63, 104-108	3.4	2
112	Immunoparesis status in AL amyloidosis at diagnosis affects response and survival by regimen type. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2017 , 24, 44-45	2.7	1
111	Correlation between urine ACR and 24-h proteinuria in a real-world cohort of systemic AL amyloidosis patients. <i>Blood Cancer Journal</i> , 2020 , 10, 124	7	1
110	Testicular plasmacytoma: unique location or circumstantial presentation?. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1769-1771	1.9	1
109	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 16-17	2.2	1
108	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 49-50	2.2	1
107	Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease. <i>Blood</i> , 2019 , 134, 3510-3510	2.2	1
106	Utilizing Multiparametric Flow Cytometry to Identify Patients with Primary Plasma Cell Leukemia at Diagnosis. <i>Blood</i> , 2019 , 134, 4334-4334	2.2	1
105	Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 1905-1905	2.2	1
104	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 39-40	2.2	1
103	Presence of a Measurable M-Spike before Autologous Stem Cell Transplantation Is Associated with Shorter Survival in Patients with Light Chain Amyloidosis. <i>Blood</i> , 2020 , 136, 22-23	2.2	1
102	Atrial fibrillation (AF) in patients with CLL treated with ibrutinib: Assessing prediction models and clinical outcomes.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 7522-7522	2.2	1

101	Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival. <i>Blood</i> , 2021 , 138, 2720-2720	2.2	1
100	A Phase 1 Study of CFT7455, a Novel Degradar of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma. <i>Blood</i> , 2021 , 138, 1675-1675	2.2	1
99	Assessing the prognostic utility of smoldering multiple myeloma risk stratification scores applied serially post diagnosis. <i>Blood Cancer Journal</i> , 2021 , 11, 186	7	1
98	Graded Renal Response Criteria for Light Chain (AL) Amyloidosis. <i>Blood</i> , 2021 , 138, 2721-2721	2.2	1
97	Characteristics and risk factors for thrombosis in POEMS syndrome: A retrospective evaluation of 230 patients. <i>American Journal of Hematology</i> , 2021 ,	7.1	1
96	Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. <i>Leukemia</i> , 2021 ,	10.7	1
95	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018 , 132, 2884-2884	2.2	1
94	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018 , 132, 4152-4152		1
93	PS1162 COMBINATION THERAPY TO PREVENT IBRUTINIB WITHDRAWAL: CONTINUED IBRUTINIB WITH THE ADDITION OF VENETOCLAX AT TIME OF PROGRESSION IN IBRUTINIB-TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). <i>HemaSphere</i> , 2019 , 3, 527-528	0.3	1
92	Clinical Outcomes and Cytogenetic Features of Primary Plasma Cell Leukemia (pPCL) in the Era of Novel Agent Induction Therapy. <i>Blood</i> , 2019 , 134, 5490-5490	2.2	1
91	Colon perforation in multiple myeloma patients - A complication of high-dose steroid treatment. <i>Cancer Medicine</i> , 2020 , 9, 8895-8901	4.8	1
90	Predictors of short-term survival in Waldenström Macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2975-2979	1.9	1
89	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 47	7	1
88	The prognostic significance of del6q23 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E203-E206	7.1	1
87	PF385 ANTICOAGULATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH IBRUTINIB. <i>HemaSphere</i> , 2019 , 3, 144-145	0.3	1
86	The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM). <i>Blood Cancer Journal</i> , 2021 , 11, 158	7	1
85	The colorful landscape of multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2099-2100	1.9	0
84	Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 944-954	6.4	0

83	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018 , 132, 4460-4460	2.2	○
82	MASS-FIX for the Diagnosis of Plasma Cell Disorders: A Single Institution Experience of 4118 Patients. <i>Blood</i> , 2020 , 136, 48-49	2.2	○
81	Outcomes Following Biochemical or Clinical Progression in Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 3760-3760	2.2	○
80	Optimal Therapy for Relapsed AL Amyloidosis Post Autologous Stem Cell Transplant. <i>Blood</i> , 2019 , 134, 3171-3171	2.2	○
79	Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 355-360	2	○
78	Prognostic value of NT-ProBNP and troponin T in patients with light chain amyloidosis and kidney dysfunction undergoing autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 274-277	4.4	○
77	Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2021 , 96, E35-E38	7.1	○
76	Use of beta blockers is associated with survival outcome of multiple myeloma patients treated with pomalidomide. <i>European Journal of Haematology</i> , 2021 , 106, 433-436	3.8	○
75	Amyloid arthropathy in smoldering myeloma: Do not take it lightly. <i>Leukemia Research Reports</i> , 2021 , 15, 100242	0.6	○
74	Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2021 , 62, 3011-3018	1.9	○
73	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021 , 11, 140	7	○
72	The Efficacy and Safety of Chemotherapy-Based Stem Cell Mobilization in Multiple Myeloma Patients Who Are Poor Responders to Induction: The Mayo Clinic Experience. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 770.e1-770.e7		○
71	Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation.. <i>Blood Cancer Journal</i> , 2022 , 12, 59	7	○
70	Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.. <i>Leukemia and Lymphoma</i> , 2022 , 1-6	1.9	○
69	Safety of Sedation for Patients Undergoing Bone Marrow Biopsy and Aspiration While Febrile. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018 , 2, 26-29	3.1	
68	Unravelling hypothyroidism in AL amyloidosis: AuthorsReply. <i>Journal of Internal Medicine</i> , 2018 , 283, 108	10.8	
67	Clinical trials evaluating potential therapies for light chain (AL) amyloidosis. <i>Expert Opinion on Orphan Drugs</i> , 2017 , 5, 655-663	1.1	
66	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020 , 136, 9-10	2.2	

65	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. <i>Blood</i> , 2020 , 136, 26-27	2.2
64	A Cross Sectional Evaluation of Light Chain N-Glycosylation By MASS-FIX in Plasma Cell Disorders. <i>Blood</i> , 2020 , 136, 44-45	2.2
63	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020 , 136, 3-4	2.2
62	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 12-13	2.2
61	Treatments and Outcomes of Newly Diagnosed Multiple Myeloma Patients > 75 Years Old: A Retrospective Analysis. <i>Blood</i> , 2020 , 136, 14-15	2.2
60	Prognostic Restaging after Treatment Initiation in Patients with AL Amyloidosis. <i>Blood</i> , 2020 , 136, 6-7	2.2
59	Outcomes of Multiple Myeloma Patients with Del 17p Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 21-22	2.2
58	Autologous Stem Cell Transplantation for Multiple Myeloma Patients Aged ≥75 Treated with Novel Agents. <i>Blood</i> , 2020 , 136, 12-13	2.2
57	Prevalence of Familial Plasma Cell Disorders in Patients with Multiple Myeloma. <i>Blood</i> , 2020 , 136, 1-2	2.2
56	Decreased Cardiac Ejection Fraction Is Associated with Worse Survival in Patients with Light Chain Amyloidosis Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2020 , 136, 41-42	2.2
55	Use of Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation (AF) in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 50-51	2.2
54	Tracking Daratumumab Clearance Using Mass Spectrometric Approaches: Implications on M Protein Monitoring and Reusing Daratumumab. <i>Blood</i> , 2021 , 138, 2707-2707	2.2
53	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFNENIS). <i>Blood</i> , 2021 , 138, 1333-1333	2.2
52	Prognostic Role of IL-6 in POEMS Syndrome. <i>Blood</i> , 2021 , 138, 2700-2700	2.2
51	Monoclonal Proteinuria Predicts Progression Risk in Asymptomatic Multiple Myeloma with a Free Light Chain Ratio ≥100. <i>Blood</i> , 2021 , 138, 1617-1617	2.2
50	Second Line Treatment Strategies in Multiple Myeloma: A Referral-Center Experience. <i>Blood</i> , 2021 , 138, 819-819	2.2
49	Amyloidosis Composite Response Score Incorporating the Depth of Organ Response. <i>Blood</i> , 2021 , 138, 3805-3805	2.2
48	Prognostic Factors for Early (<2 years) and Late (>5 years) Relapse in Multiple Myeloma- Pivotal Role of Cytogenetic Changes. <i>Blood</i> , 2021 , 138, 3761-3761	2.2

47	Outcomes of Triple Class (Proteasome Inhibitor, IMiDs and Monoclonal Antibody) Refractory Patients with Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1632-1632	2.2
46	The Role of Non-Coding RNAs in the Pathogenesis of AL Amyloidosis. <i>Blood</i> , 2021 , 138, 2659-2659	2.2
45	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory). <i>Blood</i> , 2021 , 138, 1560-1560	2.2
44	The Prognostic Utility of Serial MASS-FIX in Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1619-1619	2.2
43	Assessing the Prognostic Utility of the Mayo 2018 and IMWG 2020 Smoldering Multiple Myeloma Risk Stratification Scores When Applied Post Diagnosis. <i>Blood</i> , 2021 , 138, 543-543	2.2
42	Factors Associated with Renal Impairment at Diagnosis in Multiple Myeloma with Survival Trends over Last Two Decades. <i>Blood</i> , 2021 , 138, 1630-1630	2.2
41	Mortality Trends in Multiple Myeloma after the Introduction of Novel Therapies in the United States. <i>Blood</i> , 2021 , 138, 119-119	2.2
40	The Impact of the Central Carbon Energy Metabolism Transcriptome in the Pathogenesis and Outcomes of Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2650-2650	2.2
39	Long-Term Survivorship with Active Multiple Myeloma. <i>Blood</i> , 2018 , 132, 1912-1912	2.2
38	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). <i>Blood</i> , 2018 , 132, 3116-3116	2.2
37	Comparative Analysis of Staging Systems in AL Amyloidosis. <i>Blood</i> , 2018 , 132, 3228-3228	2.2
36	Bortezomib, Lenalidomide and Dexamethasone (VRD) Followed By Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma; The Mayo Clinic Experience. <i>Blood</i> , 2018 , 132, 2147-2147	2.2
35	Long-Term AL Amyloidosis Survivors Among Non-Selected Referral Population. <i>Blood</i> , 2018 , 132, 3226-3226	2.2
34	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. <i>Blood</i> , 2018 , 132, 1857-1857	2.2
33	Mass Spectrometry to Measure Response in Immunoglobulin Light Chain Amyloidosis (AL). <i>Blood</i> , 2018 , 132, 4502-4502	2.2
32	Prognostic Restaging at the Time of 2nd-Line Therapy in Patients with AL Amyloidosis. <i>Blood</i> , 2018 , 132, 5594-5594	2.2
31	Optimizing Deep Response Assessment for AL Amyloidosis Using Involved Free Light Chain Level at End of Therapy. <i>Blood</i> , 2018 , 132, 3227-3227	2.2
30	Plasma Cell Disorders in Patients with Age-Related Transthyretin (ATTRwt) Amyloidosis. <i>Blood</i> , 2018 , 132, 5610-5610	2.2

29	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018 , 132, 3268-3268	2.2
28	Three Decades of Autologous Stem Cell Transplantation for Myeloma; Trends in Early Mortality and Survival. <i>Blood</i> , 2018 , 132, 3436-3436	2.2
27	Patient-Reported Outcome Driven Case Management System for Hematology In Prospective Study. <i>Blood</i> , 2018 , 132, 719-719	2.2
26	PS1397 OUTCOMES OF LONG-TERM SURVIVORS WITH ACTIVE MULTIPLE MYELOMA. <i>HemaSphere</i> , 2019 , 3, 641	0.3
25	Delayed Neutrophil Engraftment in Patients Receiving Daratumumab As Part of Their First Induction Regimen for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4505-4505	2.2
24	Hypovitaminosis D Is Prevalent in Patients with Renal AL Amyloidosis and Associated with Non-t(11;14). <i>Blood</i> , 2019 , 134, 5523-5523	2.2
23	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019 , 134, 1532-1532	2.2
22	Impact of sFLC Ratio on Outcome in Patients with MM: Validating the Utility of sFLC in Response Definition. <i>Blood</i> , 2019 , 134, 3080-3080	2.2
21	Determinants of Clinical Trial Participation and Impact on Survival Outcomes Among Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 5833-5833	2.2
20	Increased Mean Corpuscular Volume Is an Independent Predictor for Worse Overall Survival in Patients with Newly Diagnosed Light Chain Amyloidosis. <i>Blood</i> , 2019 , 134, 5532-5532	2.2
19	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2019 , 134, 3037-3037	2.2
18	The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2019 , 134, 2197-2197	2.2
17	Depth of response prior to autologous stem cell transplantation to predict survival in light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8516-8516	2.2
16	Correlation between 24-hour proteinuria and spot urine albumin to creatinine ratio in systemic light chain amyloidosis.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 8549-8549	2.2
15	Assessing the utility of monitoring IgA multiple myeloma patients with quantitative serum IgA levels.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20515-e20515	2.2
14	Bone Mineral Density Utilization in Patients with Newly Diagnosed Multiple Myeloma: A Single Center Experience. <i>Blood</i> , 2015 , 126, 5386-5386	2.2
13	Efficacy and Safety of Salvage Therapy Using Carfilzomib for Relapsed or Refractory Multiple Myeloma Patients: A Multicentre Retrospective Observational Study. <i>Blood</i> , 2015 , 126, 5371-5371	2.2
12	The impact of novel induction regimens on transplant outcome in newly diagnosed multiple myeloma after controlling for high-risk FISH cytogenetics.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8033-8033	2.2

- 11 Immunoparesis in newly diagnosed AL amyloidosis as a marker for response and survival.. *Journal of Clinical Oncology*, **2016**, 34, 8016-8016 2.2
- 10 A Risk Stratification Model Using Quantification of Circulating Plasma Cells in Multiple Myeloma Prior to Autologous Stem Cell Transplantation in the Era of Novel Agents. *Blood*, **2016**, 128, 996-996 2.2
- 9 Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden. *Blood*, **2016**, 128, 3273-3273 2.2
- 8 Fluorescence in-Situ Hybridization (FISH) Analysis in Untreated AL Amyloidosis Has an Independent Prognostic Impact By Abnormality Type and Treatment Category. *Blood*, **2016**, 128, 3269-3269 2.2
- 7 Prognostic impact of kinetics of circulating plasma cells before and after induction therapy in newly diagnosed multiple myeloma patients undergoing early transplantation.. *Journal of Clinical Oncology*, **2017**, 35, 8020-8020 2.2
- 6 Overuse of organ biopsies in immunoglobulin light chain (AL) amyloidosis: The consequence of failure of early recognition.. *Journal of Clinical Oncology*, **2017**, 35, e19532-e19532 2.2
- 5 Post-Transplant Lymphoproliferative Disorder in Lung Transplant Recipients ↳ Shift Lo Late Onset Disease. *Blood*, **2012**, 120, 5075-5075 2.2
- 4 67-Year-Old Man With Fatigue, Lightheadedness, and Erythrocytosis. *Mayo Clinic Proceedings*, **2021**, 96, 1949-1954 6.4
- 3 Lenalidomide - the new melphalan?. *Leukemia and Lymphoma*, **2016**, 57, 1749-50 1.9
- 2 Prognostic Implications of Rising Serum Monoclonal Protein and Free Light Chains after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma. *Transplantation and Cellular Therapy*, **2021**, 27, 309.e1-309.e5
- 1 Success of the autologous stem cell boost after autologous graft failure in multiple myeloma and AL amyloidosis.. *Bone Marrow Transplantation*, **2022**, 4.4